Moderna Stock Sees Volatility After Cancer Vaccine Trial Results
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
Moderna Stock Sees Volatility After Cancer Vaccine Trial Results
- Moderna's stock surged by 177% on Wednesday, August 19, 2026, following positive Phase 3 trial results for its personalized melanoma vaccine, intismeran, developed with Merck & Co..
- The experimental treatment, combining intismeran and Merck's Keytruda, demonstrated statistically significant and clinically meaningful improvements in delaying disease recurrence and spread in melanoma patients..
Full Summary — powered by AI
Moderna’s stock experienced significant volatility this week, initially soaring by 177% on Wednesday, August 19, 2026, after the announcement of successful Phase 3 clinical trial results for its personalized mRNA cancer vaccine.. Developed in partnership with Merck & Co., the vaccine, known as intismeran (or mRNA-4157), in combination with Merck’s immunotherapy Keytruda, met its primary and key secondary endpoints in patients with high-risk melanoma who had their tumors surgically removed.. The trial, INTerpath-001, enrolled 1,137 patients and showed that the combination therapy significantly improved recurrence-free survival and prolonged survival without distant metastasis compared to Keytruda alone..
Despite the promising results, which led to Moderna’s best single-day gain since its IPO and inflicted an estimated $5.5 billion loss on short sellers, the stock saw a decline of approximately 18-20% on Thursday, August 20, 2026.. This pullback is attributed to investors taking profits after the substantial surge and analysts reassessing the company’s valuation.. While several banks raised their price targets, some maintained “hold” or “equal weight” ratings, with average target prices still below Wednesday’s closing price of $174.38, signaling ongoing caution regarding the stock’s long-term outlook..
The companies plan to present detailed trial data at an upcoming international medical meeting and engage with regulators for potential accelerated approval.. This marks a pivotal moment for Moderna as it seeks to diversify beyond its COVID-19 vaccine business, with this being the first successful late-stage trial for an mRNA-based cancer therapy..